Enovix Corporation Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports corporate governance and director compensation matters. The earliest reported event occurred on November 3, 2021; the filing was signed and includes a press release dated November 8, 2021. Enovix is incorporated in Delaware and its common stock and warrants trade on Nasdaq under ENVX and ENVXW, respectively.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or operating guidance. It is not an earnings or financial-results filing.
Material Changes
- The board increased its authorized size to nine directors.
- Pegah Ebrahimi was elected to the board for a term expiring at the 2022 annual meeting of stockholders.
- Ms. Ebrahimi was appointed to the Audit Committee.
- The filing states that there was no arrangement or understanding between Ms. Ebrahimi and the company or any other person regarding her election.
Compensation, Outlook, and Risks
- Ms. Ebrahimi will receive an annual board cash retainer of $45,000 and an annual Audit Committee fee of $7,500, paid quarterly in arrears.
- She received an RSU award valued at $455,000, vesting quarterly over three years.
- She also received an RSU award valued at approximately $61,370, vesting quarterly over one year, subject to earlier full vesting upon the applicable 2022 annual meeting or the one-year anniversary of the grant.
- Under the non-employee director compensation policy, her unvested equity awards will vest immediately before a change of control.
- She will enter into the company’s standard indemnification agreement.
Investor Verification Points
- Verify the effective filing and event dates, because the report identifies November 3, 2021 as the earliest event date but is signed November 8, 2021 and references a press release dated November 8.
- Review the company’s 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy for the precise share counts, vesting terms, and change-of-control provisions.
- Assess the potential dilution and ongoing compensation expense associated with the two RSU awards.
- Review Exhibit 99.1 for additional commentary regarding Ms. Ebrahimi’s appointment.